anti-MYD88 antibody product blog
Tags: Antibody; Monoclonal Antibody; MyD88; anti-MYD88 antibody; Myeloid Differentiation Primary Response 88;
The MYD88 myd88 (Catalog #MBS140465) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. MyBioSource\'s Myeloid Differentiation Primary Response 88 can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), Western Blot (WB).The antibody has been tested by ELISA, Western blot analysis to assure specificity and reactivity. Since application varies, however, each investigation should be titrated by the reagent to obtain optimal results. Recommended starting dilution is 1:1000. Researchers should empirically determine the suitability of the MYD88 myd88 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The MYD88 myd88 product has the following accession number(s) (GI #15488923) (NCBI Accession #AAH13589.1). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Introduction: Myeloid differentiation primary response gene 88 (MYD88) is a cytosolic adapter protein, which has a central role in the innate and adaptive immune response. MYD88 functions as a vital signal transducer in the interleukin-1 and Toll-like receptor signaling pathways. MYD88 acts via IRAK1, IRAK2, IRF7 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. The MYD88 protein increases IL-8 transcription. MYD88 is involved in IL-18-mediated signaling pathway. MYD88 activates IRF1, resulting in its rapid migration into the nucleus to mediate an efficient induction of IFN-beta, NOS2/INOS, and IL12A genes. MYD88 is comprised of an N-terminal death domain and a C-terminal Toll-interleukin1 receptor domain. Patients with defects in the MYD88 gene have an increased susceptibility to pyogenic bacterial infections.
Immunogen: Anti-human MYD88 mAb, clone PAT22F11A, is derived from hybridization of mouse F0 myeloma cells with spleen cells from BALB/c mice immunized with a recombinant human MYD88 protein 1-309 amino acids purified from E Coli. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing MYD88 are readily searchable from our website. Different antibodies against the same target such as MYD88 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results. MYD88 also interacts with the following gene(s): FADD, IL1R1, IRAK1, IRAK2, IRAK4, IRF7, TIRAP, TLR2, TLR4, TLR9. Blood, Bone, Bone Marrow, Brain, Intestine, Kidney, Liver, Lung, Spleen, Vascular tissues are correlated with this protein.